LCTX Lineage Cell Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 876343 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.2%
TTM net income YoY102.6%
TTM EPS YoY69.0%
Revenue 3-yr CAGR7.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-280.3%
Net margin16.2%
FCF margin-244.1%
EBITDA margin-273.3%
Returns
ROE3.9%
ROA1.8%
ROIC (approx.)-216.8%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio5.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-14.73x
Accruals ratio29.1%
Payout ratio—
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $14.56M | $9.50M |
| Cost of revenue | — | $334,000 |
| Gross profit | — | $9.16M |
| R&D expense | $17.73M | $12.47M |
| SG&A expense | $18.46M | $18.17M |
| Operating income | -$36.62M | -$21.48M |
| Pretax income | -$68.65M | -$18.58M |
| Income tax | -$5.28M | $0 |
| Net income | -$63.53M | -$18.61M |
| EBITDA | -$35.92M | -$20.89M |
| EPS (basic) | -0.28 | -0.09 |
| EPS (diluted) | -0.28 | -0.09 |
| Weighted avg. shares (diluted) | 230.12M | 200.19M |
| Balance sheet | ||
| Cash & equivalents | $40.79M | $46.35M |
| Short-term investments | $14.99M | $2.02M |
| Receivables | $891,000 | $638,000 |
| Current assets | $59.16M | $51.00M |
| PP&E, net | $2.57M | $2.25M |
| Goodwill | $10.67M | $10.67M |
| Intangibles | $31.70M | $46.54M |
| Total assets | $112.58M | $113.22M |
| Current liabilities | $11.37M | $13.98M |
| Total liabilities | $69.24M | $36.21M |
| Shareholders' equity | $44.55M | $78.38M |
| Shares outstanding | 243.12M | 220.42M |
| Cash flow statement | ||
| Operating cash flow | -$18.92M | -$23.09M |
| Capital expenditure | $522,000 | $565,000 |
| Free cash flow | -$19.44M | -$23.66M |
| Investing cash flow | -$13.46M | -$2.31M |
| Financing cash flow | $26.95M | $35.86M |
| Depreciation & amortization | $699,000 | $587,000 |
| Stock-based compensation | $4.75M | $5.08M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.